Drug Insights

Harnessing Synapse for Triamcinolone Information: Strategies and Tips

12 March 2024
2 min read

Triamcinolone, an exogenous synthetic corticosteroid, functions as a high-affinity agonist of the glucocorticoid receptor (GR), which is predominantly employed in the treatment of autoimmune disorders encompassing psoriasis, lupus, and rheumatoid arthritis, amongst others. The said chemical entity was developed and brought to market by Astellas Pharma, Inc., having secured regulatory approval for therapeutic use as far back as 1996. Depending on the gravity and location of the condition being managed, triamcinolone can be administered in a multitude of formulations, ranging from injectables to topicals and inhalers. Despite its established therapeutic value in the management of a diverse range of autoimmune disorders, the chemical entity has the potential to evoke an array of unwanted effects, including but not limited to mood changes, weight gain, and fluid retention, especially in a subset of the patient population. Click on the image below to begin the exploration journey of Triamcinolone through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Amylyx Reveals Key Findings from Worldwide Stage 3 PHOENIX Study on AMX0035 for ALS Treatment
Latest Hotspot
3 min read
Amylyx Reveals Key Findings from Worldwide Stage 3 PHOENIX Study on AMX0035 for ALS Treatment
12 March 2024
Amylyx Pharmaceuticals released initial results from their Phase 3 PHOENIX study, a 48-week global, randomized, double-blind, placebo-controlled trial, assessing AMX0035 in ALS patients.
Read →
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
Hot Spotlight
4 min read
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
12 March 2024
Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.
Read →
VISEN Announces China's Approval to Submit Lonapegsomatropin Biologic License
Latest Hotspot
3 min read
VISEN Announces China's Approval to Submit Lonapegsomatropin Biologic License
12 March 2024
VISEN Reveals China's Endorsement of Submission for the Biologic Drug License Concerning Lonapegsomatropin.
Read →
Effortless Searching: How to Find Nifedipine on Synapse
Drug Insights
2 min read
Effortless Searching: How to Find Nifedipine on Synapse
12 March 2024
Nifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.